贝尔生物60岁女董事长邵育晓控股49.8%，曾任职北京肝炎试剂研制中心

Core Viewpoint - Beijing Beier Bioengineering Co., Ltd. (Beier Bio) has received approval for its IPO on the Beijing Stock Exchange, with a focus on in vitro diagnostic reagents and instruments, showcasing strong revenue growth and profitability metrics [2][3]. Company Overview - Beier Bio was established on September 14, 1995, and is recognized as a national-level specialized and innovative "little giant" enterprise [2]. - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and supporting instruments, with product lines covering various fields such as respiratory pathogens, reproductive health, hepatitis viruses, gastrointestinal pathogens, EB virus, and autoimmune antibodies [2]. Financial Performance - Revenue projections for Beier Bio from 2022 to 2024 are as follows: 275 million yuan, 413 million yuan, and 376 million yuan, respectively [2]. - Net profit for the same period is projected to be 44.18 million yuan, 149 million yuan, and 140 million yuan, respectively [2]. - Gross profit margins are expected to increase from 71.24% in 2022 to 78.88% in 2024 [2]. Key Financial Metrics - Total assets as of December 31, 2024, are projected to be approximately 863.73 million yuan, up from 648.93 million yuan in 2022 [3]. - Shareholder equity is expected to rise to approximately 789.96 million yuan by the end of 2024, compared to 477.06 million yuan in 2022 [3]. - The company's debt-to-asset ratio is projected to decrease significantly from 23.88% in 2022 to 7.83% in 2024 [3]. Shareholding Structure - Shao Yuxiao directly holds 18.04 million shares, accounting for 24.06% of the total share capital, and indirectly holds an additional 1.28 million shares through other entities, totaling 49.82% of the company's shares [4]. Leadership Background - Shao Yuxiao, born on June 30, 1965, has over 20 years of experience in the R&D management of in vitro diagnostic reagents and has held various leadership positions since 2002 [6]. - She has been instrumental in developing the enzyme-linked immunosorbent assay (ELISA) platform and has received multiple certifications for diagnostic kits since 2006 [6].